Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis-Reference-Cited by-同舟云学术

Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis

Published:2022-10-25 Issue:3 Volume:29 Page:466-470
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Calocer Floriane¹^ORCID,Ng Huah Shin¹^ORCID,Zhu Feng¹,Zhao Yinshan¹,Dejardin Olivier²,Leray Emmanuelle³,Defer Gilles⁴,Evans Charity⁵,Fisk John D⁶,Marrie Ruth Ann⁷^ORCID,Tremlett Helen¹^ORCID

Affiliation:

1. Department of Medicine, Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, UBC Hospital, Vancouver, BC, Canada

2. UNICAEN, CHU de Caen, INSERM U1086 ANTICIPE, Pôle de Recherche, Normandie University, Caen, France

3. EHESP Rennes, Sorbonne Paris Cité, Rennes, France; CIC-P 1414, CHU Rennes, West Neuroscience Network of Excellence (WENNE), Rennes, France

4. UNICAEN, CHU de Caen Normandie Department of Neurology, MS Expert Center, Normandie University, Caen, France; Réseau Bas-Normand Pour la Prise en Charge de la SEP, Caen, France

5. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada

6. Nova Scotia Health Authority and the Departments of Psychiatry, Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax, NS, Canada

7. Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Abstract

Background: The relationship between socioeconomic status (SES) and mortality among persons with multiple sclerosis (PwMS) is poorly understood. Objective: To investigate the association between SES and mortality risk in PwMS. Methods: From health-administrative data, we identified 12,126 incident MS cases with a first demyelinating event (MS ‘onset’) occurring between 1994 and 2017. Cox proportional hazard model assessed the association between socioeconomic status quintiles (SES-Qs) at MS onset and all-cause mortality. Results: Lower SES-Qs were associated with higher mortality risk; adjusted hazard ratios: SES-Q1 (most deprived) =1.61 (95% confidence interval (CI) = 1.36–1.91); SES-Q2 = 1.26 (95% CI = 1.05–1.50); SES-Q3 = 1.22 (95% CI = 1.02–1.46); SES-Q4 = 1.13 (95% CI = 0.94–1.35) versus SES-Q5 (least deprived). Conclusion: A lower SES was associated with higher mortality risk in PwMS.

Funder

Fondation pour l’Aide à la Recherche sur la Sclérose en Plaques

Canadian Institutes of Health Research (CIHR) Project and Foundation grant

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585221129963

Reference15 articles.

1. Socioeconomic status and disability progression in multiple sclerosis

2. Is high socioeconomic status a risk factor for multiple sclerosis? A systematic review

3. Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women

4. British Columbia Ministry of Health. Medical services plan (MSP) payment information file (V2, Data Extract, MOH). Population Data BC, 2017, http://www.popdata.bc.ca/data

5. Canadian Institute for Health Information. Discharge abstract database (Hospital Separations, V2, Data Extract, MOH). Population Data BC, 2017, http://www.popdata.bc.ca/data

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08

2. A Framework for Addressing Health Disparities in Adult Neurogenic Lower Urinary Tract Dysfunction—Systematic Review and Neurogenic Bladder Research Group Recommendations;Urologic Clinics of North America;2024-05

3. Effects of financial toxicity and socioeconomic status on MRI follow‐up time in multiple sclerosis;Clinical Neuroimaging;2024-03

4. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges;The Lancet Neurology;2024-03

5. Natural History of Keloids: A Sociodemographic Analysis Using Structured and Unstructured Data;Dermatology and Therapy;2023-12-08